CYP 2021 - The year ahead, page-460

March 2021 Quarterly Activity Report
Melbourne, Australia; 27 April 2021: Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the
“Company”), a clinical‐stage biotechnology company specialising in cell therapeutics, has today
released its Quarterly Activity Report for the three‐month period ended 31 March 2021.

Key highlights

 Phase 3 Osteoarthritis clinical trial actively recruiting and treating patients, following
successful completion of the follow‐up of the initial subjects

 Ethics approval received for the MEND clinical trial recruitment criteria to be expanded to a
broader group of patients experiencing respiratory distress (beyond COVID‐19)

 Progress made in planning for clinical trials in the high priority indications of diabetic foot
ulcers (DFU), idiopathic pulmonary fibrosis (IPF), and renal transplantation

 MoU signed with TekCyte to utilise advanced wound dressing technology for the proposed
DFU trial

 New pre‐clinical study commenced to investigate the biological mechanisms underpinning
the previously demonstrated high potency of Cymerus™ mesenchymal stem cells (MSCs) in
a pre‐clinical model of lung fibrosis

 Strong financial position with A$28.2m in cash as at 31 March 2021
o Includes ~A$1.4m R&D tax incentive refund received, and ~A$3.3m capital raised via a
non‐renounceable entitlement offer and partial placement of shortfall shares

EV = $56m